Matthew Solomon: Why Secondary Analyses of Clinical Trials Matter for Better Care
Matthew Solomon, Chief Scientific Officer at Sutter Health, shared a post on LinkedIn about a recent article by Harlan Krumholz and Harold Hines, published in JACC:
”Going through my stack of JACCs and this one really caught my eye
Kudos to the editorial team at the Journal of the American College of Cardiology for dedicating an entire issue to secondary analyses of clinical trials. It’s easy to focus only on primary endpoints, but there’s so much valuable learning in what comes next.
While some secondary results are hypothesis-generating, many offer critical clinical insights that help us understand nuances in treatment effects, patient subgroups, long-term outcomes, and underlying biology. Shining a spotlight on this work helps us translate trial evidence into better care.
Big thanks to the editors for the emphasis on this often under-appreciated yet essential part of clinical research.
What secondary analyses can do:
- Reveal effects in subpopulations that weren’t the focus of the primary endpoint
- Explore mechanistic insights or biological signals not captured by the primary outcome
- Extend follow-up to look at longer-term outcomes
- Refine endpoints or composite outcomes for future trials
- Test consistency of effects across methods or clinical contexts
These analyses help close gaps between trial results and real-world practice – and that’s why they matter.”
Title: When the Trial Is Over: What Secondary Analyses Still Teach Us
Authors: Harlan Krumholz, Harold Hines
Read the Full Article on Journal of the American College of Cardiology
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026